Artimplant invests in expanded own sales

With effect from January 1, 2012, Artimplant will take over responsibility for sales of Artelon® CMC Spacer, previously handled by the licensee SBi. This is an integral part of Artimplant's focus on reinforcing its presence on the very important US market.

Since December 2011, Artimplant has had a stronger sales organization in place in the USA, which it is felt will contribute positively to the company's presence and sales volumes. By assuming responsibility for sales of Artelon® CMC Spacer and other products for restoring joint surfaces, Artimplant will have a more complete product offering on the US market. Artelon® CMC Spacer is considered to have major market potential, which Artimplant is in a better position to develop by assuming direct control of sales.

The former licensee, SBI, will cease sales of Artimplant products for restoring joint surfaces in conjunction with Artimplant taking back the sales rights for these products.

Västra Frölunda, January 3, 2012
Kjell Thörnbring


For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html


Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on January 3, 2012 at 11:00 AM (Swedish time).

Tags: